Results 61 to 70 of about 1,913 (212)

Implantable Drug Delivery Systems for Skeletal Muscles and Eyes

Advanced NanoBiomed Research, Volume 6, Issue 2, February 2026.
This review highlights the different types of recent implantable drug delivery systems (IDDS) fabricated for a use with skeletal muscles, and with eyes. It presents the developments already made and the current research directions, showing the evolution of IDDS and their great diversity.
Serge Ostrovidov, Murugan Ramalingam, Hongkai Wu, Toshinori Fujie, Yukinari Nakamura, Takeshi Hori, Yuji Nashimoto, Xuetao Shi, Hirokazu Kaji   +8 more
wiley   +1 more source

Mass spectrometry in ocular drug research

Mass Spectrometry Reviews, Volume 45, Issue 1, Page 37-68, January/February 2026.
Abstract Mass spectrometry (MS) has been proven as an excellent tool in ocular drug research allowing analyzes from small samples and low concentrations. This review begins with a short introduction to eye physiology and ocular pharmacokinetics and the relevance of advancing ophthalmic treatments.
Eva M. del Amo, Kati‐Sisko Vellonen, Arto Urtti, Tetsuya Terasaki, Anam Hammid, Paavo Honkakoski, Seppo Auriola   +6 more
wiley   +1 more source

A low concentration of Tacrolimus/semifluorinated alkane (SFA) eyedrop suppresses intraocular inflammation in experimental models of uveitis [PDF]

, 2017
PURPOSE: Corticosteroids remain the mainstay therapy for uveitis, a major cause of blindness in the working age population. However, a substantial number of patients cannot benefit from the therapy due to steroids resistance or intolerance.
De Majumdar, S, Korward, J, Pettigrew, Andrew, Scherer, D, Subinya, M, Xu, H   +5 more
core   +3 more sources

Prognostic biomarkers of chronic diabetic macular edema treated with a fluocinolone acetonide intravitreal implant [PDF]

, 2021
Background: This study aimed to investigate retinal imaging biomarkers, such as disorganization of the retinal inner layers (DRIL) and/or ellipsoid zone (EZ) disruption by spectral domain optical coherence tomography (SD-OCT), and functional outcomes in ...
Aerts , Florence, Brizido, Margarida Sena, Lopes, Beatriz Oliveira, Miranda, Margarida Isidoro, Pina, Susana Morais, Simoes, Pedro Santana   +5 more
core   +2 more sources

Recent Investigations on Pathogenesis, Biomarkers, Epigenetics, and Emerging Therapeutic Strategies to Modulate Multiple Signaling Pathways in Diabetic Retinopathy

Journal of Ophthalmology, Volume 2026, Issue 1, 2026.
Background Diabetic retinopathy (DR) is a progressive microvascular complication related to diabetes mellitus and remains a profound cause of vision impairment and blindness globally. In addition to its ocular manifestations, DR is increasingly recognized as a main risk factor for systemic diseases, including cardiovascular and neurodegenerative ...
Zixuan Huang, Jing Wei, Dayong Yang, Kofi Asiedu   +3 more
wiley   +1 more source

Corticosteroids for diabetic macular edema

Taiwan Journal of Ophthalmology, 2019
Diabetic macular edema (DME) is a chronic condition with a multifactorial pathogenesis. Vascular endothelial growth factor (VEGF) and several inflammatory mediators are upregulated in eyes with DME.
Jorge Chawan-Saad, Max Wu, Andres Wu, Lihteh Wu   +3 more
doaj   +1 more source

Intravitreal Fluocinolone Acetonide for Diabetic Macular Edema: Long-Term Effect and Structure/Function Correlation [PDF]

, 2022
The long-term effect of intravitreal Fluocinolone acetonide (FAc) on retinal morphology and function in diabetic macular edema (DME) was investigated. Seventeen eyes of twelve consecutive DME patients, treated by intravitreal FAc, were retrospectively ...
Falsini, Benedetto (ORCID:0000-0002-3569-4968), Maceroni, Martina, Minnella, Angelo Maria (ORCID:0000-0001-5896-5313), Placidi, Giorgio, Rizzo, Stanislao (ORCID:0000-0001-6302-063X)   +4 more
core   +1 more source

Efficacy of Low-Release-Rate Fluocinolone Acetonide Intravitreal Implants to Treat Experimental Uveitis [PDF]

Archives of Ophthalmology, 2006
To determine the efficacy of 0.5-mg and 0.1-mg sustained-release fluocinolone acetonide intravitreal implants to inhibit ocular inflammation in a rabbit model of severe uveitis.The in vitro pharmacokinetic profile of both the 0.5-mg and 0.1-mg sustained-release fluocinolone intravitreal implants was determined during a 10-day period.
Prithvi, Mruthyunjaya, Dara, Khalatbari, Ping, Yang, Sandra, Stinnett, Ryotaro, Tano, Paul, Ashton, Hong, Guo, Marty, Nazzaro, Glenn J, Jaffe   +8 more
openaire   +2 more sources

Stimuli‐responsive systems: A focus on controlled drug delivery for posterior segment ocular disease

Responsive Materials, Volume 3, Issue 4, November 2025.
This review highlights recent advances in stimuli‐responsive drug delivery for posterior segment diseases, focusing on mechanisms and potential. It also explores mechanically interlocked molecules and bioorthogonal reactions as novel approaches. Challenges and future perspectives are discussed, aiming to bridge the gap between research and clinical ...
Chengzhi Zhang, Jiayi Hou, Yameng Zhao, Yiwen Wang, Kexin Wang, Siyu Li, Yange Wang, Jiehao Zhang, Shenao Ding, Chenxu Zhang, Zongming Song, Ye Tao   +11 more
wiley   +1 more source

Long-Acting Fluocinolone Acetonide Intravitreal Implant for Recurrent Bilateral Non-Infectious Posterior Uveitis

International Medical Case Reports Journal, 2022
Adrian T Babel,1,2 Eric K Chin,3,4 David RP Almeida2 1Boonshoft School of Medicine, Dayton, OH, USA; 2Erie Retinal Surgery, Erie, PA, USA; 3Retina Consultants of Southern California, Redlands, CA, USA; 4Loma Linda Eye Institute, Veterans Affair Hospital,
Babel AT, Chin EK, Almeida DRP
doaj